Hemodialysis patients with coronavirus disease 2019: reduced antibody response.

Hiroko BeppuTatsuya FukudaTomoko KawanishiFumihiko YasuiMinami TodaHitomi KimuraYuki NakamuraYuka NakamuraKaori KojimaHina OgawaAyumi IshiwatariYuiko KameiToshie OgawaYasutomo AbeMariko EndoTomohide HanawaRie MizobuchiChise SugitaKoh OkamotoShuji HatakeyamaTetsusya YamadaMichinori KoharaSachiko Wakai

Published in: Clinical and experimental nephrology (2021)

COVID-19 patients with severe disease, especially those undergoing HD, had lower IgG-S1 production in the second week of the disease. Thus, the increased risk of severe COVID-19 in HD patients may be, in part, due to a slow and reduced antibody response.

Keyphrases

coronavirus disease
end stage renal disease
chronic kidney disease
sars cov
peritoneal dialysis
ejection fraction
early onset
newly diagnosed
respiratory syndrome coronavirus
prognostic factors
clinical trial
randomized controlled trial
patient reported outcomes
drug induced
patient reported